Why the study?
Recurrence and phenotypic change of takotsubo syndrome are rare, with previously reported cases occurring months to years after initial diagnosis.
Does combined treatment with β-blockers and ACE inhibitors or ARBs prevent the recurrence of takotsubo syndrome compared to monotherapies?
Does combined treatment with β-blockers and ACE inhibitors or ARBs prevent the recurrence of takotsubo syndrome compared to monotherapies?
Combined therapy with beta-blockers and ACEi/ARBs may be more effective than monotherapy in preventing the rare short-term recurrence of takotsubo syndrome.
Answers are grounded in this paper and cite their sources.
May support combined β-blocker and ACEi/ARB therapy to reduce takotsubo recurrence; leaves open confirmation in prospective trials.
Recurrence and phenotypic change of TTS are rare. Some cases have been reported but occurring months to years after initial diagnosis. Combined treatment with β-blockers and angiotensin-converting enzyme inhibitors or angiotensin receptor antagonists may be more effective to prevent the recurrence than monotherapies.
No takes yet. Share an insight, caveat, or question.
Saito et al. (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: